Download
s41416-020-01255-z.pdf 356,18KB
WeightNameValue
1000 Titel
  • Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
1000 Autor/in
  1. Waller, Cornelius |
  2. Möbius, Julia |
  3. Fuentes-Alburo, Adolfo |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-16
1000 Erschienen in
1000 Quellenangabe
  • 124(8):1346-1352
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41416-020-01255-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039027/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Trastuzumab was originally approved as an intravenous (IV) formulation but has since been developed for subcutaneous (SC) administration for patients with HER2-positive breast cancer. Both formulations demonstrate generally comparable pharmacological and clinical profiles. Therefore, when deciding between treatment options, factors such as the route of administration, patient preference, value and cost must be considered. Studies comparing IV with SC trastuzumab indicate that each formulation offers unique advantages to patients depending on their individual needs. Concurrent with the development of SC trastuzumab, IV trastuzumab biosimilars comprise another treatment option that, in view of their reduced cost, might improve patient access and increase cost-effectiveness for healthcare providers and payers. In this review, we seek to raise awareness of the current options available for trastuzumab so that healthcare providers can optimally treat patients according to their individual situations and preferences.
1000 Sacherschließung
lokal Female [MeSH]
lokal Cost-Benefit Analysis [MeSH]
lokal Humans [MeSH]
lokal Trastuzumab/administration
lokal Breast Neoplasms/genetics [MeSH]
lokal Breast cancer
lokal Treatment Outcome [MeSH]
lokal Administration, Intravenous/economics [MeSH]
lokal Breast Neoplasms/drug therapy [MeSH]
lokal Review Article
lokal Receptor, ErbB-2/genetics [MeSH]
lokal Biosimilar Pharmaceuticals/administration
lokal Injections, Subcutaneous/economics [MeSH]
lokal Trastuzumab/economics [MeSH]
lokal Biosimilar Pharmaceuticals/economics [MeSH]
lokal Clinical Trials as Topic [MeSH]
lokal Chemotherapy
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-5777-0212|https://frl.publisso.de/adhoc/uri/TcO2Yml1cywgSnVsaWE=|https://frl.publisso.de/adhoc/uri/RnVlbnRlcy1BbGJ1cm8sIEFkb2xmbw==
1000 Hinweis
  • DeepGreen-ID: bad15570f7db4d7c99bd13a56d6e661e ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6442894.rdf
1000 Erstellt am 2023-04-26T16:09:57.054+0200
1000 Erstellt von 322
1000 beschreibt frl:6442894
1000 Zuletzt bearbeitet 2023-10-19T13:36:07.744+0200
1000 Objekt bearb. Thu Oct 19 13:36:07 CEST 2023
1000 Vgl. frl:6442894
1000 Oai Id
  1. oai:frl.publisso.de:frl:6442894 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source